#1 Clinical Trials Search in Europe

Clostridia, Cluster Iv, Strain Relative Flavonifractor Plautii, Live

This article examines clinical trials investigating the use of a novel drug containing Clostridia Cluster IV strain, specifically Flavonifractor plautii, for treating intestinal conditions like Clostridioides difficile infection (CDI) and ulcerative colitis. These trials aim to evaluate the safety and efficacy of bacterial strains in managing gut microbiome-related diseases.

Table of Contents

Introduction

CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE is a promising new treatment being studied for its potential to help patients with certain gastrointestinal conditions. This article will explain what this treatment is, how it may work, and what we know so far from ongoing clinical trials.[1][2]

What is CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE?

CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE is a type of live bacterial strain that is being investigated as part of two different treatments: VE303 and VE202. These treatments are known as live biotherapeutic products (LBPs), which means they contain live organisms (in this case, bacteria) that are used to prevent, treat, or cure a disease or condition in humans.[1][2]

This specific bacterial strain is part of a larger group of bacteria called Clostridia, which are naturally found in the human gut. The “Cluster IV” designation refers to a specific group within the Clostridia family, and “Flavonifractor plautii” is the species name of this particular bacterium.[1]

Potential Uses

Based on the clinical trials currently underway, CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE is being studied for two main conditions:

  1. Clostridioides difficile Infection (CDI): This is a serious intestinal infection that can cause severe diarrhea and other complications. The VE303 treatment, which includes this bacterial strain, is being studied for preventing recurrent CDI.[1]
  2. Ulcerative Colitis (UC): This is a type of inflammatory bowel disease that causes inflammation and ulcers in the digestive tract. The VE202 treatment, which also includes this bacterial strain, is being studied for treating mild to moderate UC.[2]

Clinical Trials

Two major clinical trials are currently investigating treatments that include CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE:

  1. VE303 for CDI (RestoratiVE303 Study): This is a Phase 3 study looking at the effectiveness of VE303 in preventing recurrent CDI. The study is comparing VE303 to a placebo in patients who have recently completed antibiotic treatment for CDI.[1]
  2. VE202 for Ulcerative Colitis: This is a Phase 2 study examining the effectiveness and safety of VE202 in patients with mild to moderate ulcerative colitis.[2]

Both studies are randomized, double-blind, and placebo-controlled, which means that participants are randomly assigned to receive either the treatment or a placebo, and neither the participants nor the researchers know who is receiving which.

How It Works

While the exact mechanism of action is still being studied, it’s believed that CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE, along with the other bacterial strains in VE303 and VE202, may work by:

  • Helping to restore a healthy balance of bacteria in the gut (also known as the gut microbiome)
  • Competing with harmful bacteria like C. difficile for resources in the gut
  • Potentially modulating the immune system to reduce inflammation

These actions may help prevent the recurrence of C. difficile infections or reduce the symptoms of ulcerative colitis.[1][2]

Safety and Side Effects

As these treatments are still in clinical trials, comprehensive safety data is not yet available. However, the ongoing studies are closely monitoring for any adverse events or side effects. Some potential side effects that are being watched for include:

  • Gastrointestinal symptoms (e.g., nausea, abdominal pain, diarrhea)
  • Allergic reactions
  • Infections

It’s important to note that these are potential side effects being monitored in the trials, and not confirmed side effects of the treatment.[1][2]

Conclusion

CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE is a promising component of new treatments being studied for Clostridioides difficile infection and ulcerative colitis. While the results of these clinical trials are not yet known, this research represents an exciting new approach to treating these challenging gastrointestinal conditions. As always, patients should consult with their healthcare providers about the most appropriate treatments for their individual situations.

Aspect VE303 Trial (CDI) VE202 Trial (Ulcerative Colitis)
Condition Studied Clostridioides difficile infection (CDI) Mild-to-moderate ulcerative colitis
Primary Objective Compare CDI recurrence rate at Week 8 Evaluate endoscopic response at Day 56
Treatment Duration 14 days 8 weeks
Key Inclusion Criteria Age ≥12 years, laboratory-confirmed CDI Age 18-75, active mild to moderate UC
Primary Endpoints CDI recurrence through Week 8 Endoscopic response rate, safety profile
Administration Oral capsules Oral capsules

FAQ

  • What conditions are being studied in these clinical trials? The clinical trials are studying Clostridioides difficile infection (CDI) and mild-to-moderate ulcerative colitis.
  • What is the main drug being tested in these trials? The main drug being tested contains live bacterial strains, including Clostridia Cluster IV strain relative Flavonifractor plautii, along with other bacterial strains. It is referred to as VE303 in one trial and VE202 in another.
  • How is the drug administered in these trials? The drug is administered orally in capsule form.
  • What are the primary objectives of these trials? The primary objectives include evaluating the efficacy of the drug in preventing CDI recurrence, assessing its safety profile, and measuring its effect on endoscopic response in ulcerative colitis patients.
  • Who can participate in these trials? Eligibility varies by trial, but generally includes adults with confirmed diagnoses of the studied conditions, meeting specific criteria for disease severity and prior treatments. Some trials also include adolescents aged 12 and above for the CDI study.

Ongoing Clinical Trials on Clostridia, Cluster Iv, Strain Relative Flavonifractor Plautii, Live

  • Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

Glossary

  • Clostridioides difficile infection (CDI): A bacterial infection that causes diarrhea and inflammation of the colon, often occurring after antibiotic use disrupts the normal gut bacteria.
  • Ulcerative colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
  • Microbiota: The community of microorganisms, including bacteria, that live in a specific environment, such as the human gut.
  • Endoscopic response: An improvement in the appearance of the intestinal lining as observed through an endoscope, used to measure the effectiveness of treatments for conditions like ulcerative colitis.
  • Recurrence: The return of symptoms or infection after a period of improvement or resolution, particularly relevant in Clostridioides difficile infections.
  • Live bacterial strains: Specific types of living bacteria used as therapeutic agents to potentially improve gut health and treat various gastrointestinal conditions.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active ingredients, used as a control in clinical trials.
  • Standard of Care (SoC): The currently accepted method of treating a particular condition, often used as a comparison for new treatments in clinical trials.

References

  1. http://clinicaltrials.eu/trial/study-on-ve303-for-preventing-recurrent-c-difficile-infection-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-ve202-for-patients-with-mild-to-moderate-ulcerative-colitis/